Biophytis S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPTSY research report →
Price Chart
About the company
Biophytis S. A. is a clinical-stage biotechnology firm dedicated to developing therapeutic interventions that slow the degenerative processes associated with age and improve functional outcomes for patients.
- CEO
- Stanislas Veillet
- IPO
- 2021
- Employees
- 19
- HQ
- Paris, IF, FR
Get TickerSpark's AI analysis on BPTSY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $105.22K
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.03
- EV/EBITDA
- -1.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 153.48%
- ROIC
- -2242.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-8,500,000
- Net Income
- $-10,379,000+39.0%
- EPS
- $-2.00+98.4%
- OCF Growth
- +32.9%
- FCF Growth
- +34.0%
- 52W High
- $3.36
- 52W Low
- $0.00
- 50D MA
- $0.32
- 200D MA
- $1.48
- Beta
- 0.90
- RSI (14)
- 3
- Avg Volume
- 90
No earnings-call transcripts are available for BPTSY yet.
- Free Float
- 99.5%
- Shares Outstanding
- 420.89K
- Float Shares
- 418.68K
Our BPTSY coverage
Recent articles, reports, and earnings notes.
No research on BPTSY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BPTSY report →Biophytis Targets Mobility Restoration in Patients with Obesity
newsfilecorp.com · Apr 22
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
newsfilecorp.com · Apr 9
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
newsfilecorp.com · Mar 24
Biophytis Revolutionizes Sarcopenia
newsfilecorp.com · Mar 17
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
newsfilecorp.com · Feb 25
Biophytis Unveils Its Outlook Strategies for 2025
newsfilecorp.com · Feb 11
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
newsfilecorp.com · Jan 27
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
newsfilecorp.com · Jan 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.